Antineutrophil cytoplasmic antibodies
EstablishedANCA is the key serologic marker for a group of small-vessel vasculitis diseases.
ANCA is an antibody that helps diagnose a group of diseases causing inflammation of small blood vessels. Most patients with these diseases test positive, but a negative test doesn't rule the disease out, and doctors sometimes start treatment based on symptoms plus ANCA results without waiting for a biopsy in urgent situations.
Antineutrophil cytoplasmic antibodies (ANCA) target neutrophil granule proteins (myeloperoxidase/MPO or proteinase 3/PR3) and are the key serologic marker for ANCA-associated vasculitis (AAV), a group of small-vessel autoimmune diseases.
About 90% of patients with small-vessel vasculitis or associated glomerulonephritis are ANCA-positive, but ANCA negativity does not exclude the diagnosis. AAV encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
High-quality antigen-specific immunoassays for MPO- and PR3-ANCA are the preferred screening method per international consensus; a compatible clinical presentation with positive ANCA serology is often sufficient to begin treatment without waiting for kidney biopsy in rapidly deteriorating patients.
The KDIGO 2024 clinical practice guideline (with 2025 clarifying amendments) provides current, actively-updated treatment recommendations; persistent or rising ANCA levels may predict future disease relapse and inform treatment duration decisions.
Present in ~90% of AAV cases; guides urgent treatment decisions per current 2024/2025 KDIGO guidelines.
- KDIGO. (2024). Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis. Kidney International.